Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2934807 | 1.00 | LRRK2 (0.53) | LRRK2TTK | |
| SCHEMBL13515306 | 0.91 | LRRK2 (0.53) | LRRK2TTK | |
| SCHEMBL2927055 | 0.82 | LRRK2 (0.46) | LRRK2TTK | |
| SCHEMBL2927212 | 0.82 | LRRK2 (0.64) | LRRK2 | |
| SCHEMBL2928966 | 0.82 | TTK (0.46) | LRRK2TTK | |
| SCHEMBL2933832 | 0.82 | TTK (0.46) | LRRK2TTK | |
| SCHEMBL2935300 | 0.81 | MCHR1 (0.45) | LRRK2TTK | |
| SCHEMBL13515314 | 0.80 | LRRK2 (0.43) | LRRK2TTK | |
| SCHEMBL2931379 | 0.78 | LRRK2 (0.43) | LRRK2TTK | |
| SCHEMBL2932362 | 0.77 | LRRK2 (0.57) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039450-A1 | Compounds | NEK2, CSNK2A3, CSNK2A1 | LRRK2 309/4885TTK 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.